The Journal of Pharmaceutical and Biomedical Analysis, published by ELSEVIER and available in print and online formats, stands as a pivotal source of knowledge in the realms of Analytical Chemistry, Clinical Biochemistry, Drug Discovery, and Pharmaceutical Science. With an ISSN of 0731-7085 and an e-ISSN of 1873-264X, this journal is dedicated to publishing high-quality research that advances the understanding and development of analytical techniques in pharmaceuticals and biomedicine. The journal has earned a solid reputation, reflected in its Q2 category rankings across five distinct fields for 2023, and boasts impressive Scopus rankings, signaling its robust impact within the academic community. The Journal of Pharmaceutical and Biomedical Analysis serves as an essential resource for researchers, professionals, and students alike, providing actionable insights and fostering innovation that can directly influence future advancements in drug development and biomedical applications.

Expert Review of Proteomics, published by TAYLOR & FRANCIS LTD, is a distinguished journal that focuses on the latest advancements in the field of proteomics, a critical area within biochemistry and molecular biology. With an ISSN of 1478-9450 and E-ISSN 1744-8387, this journal has been pivotal in disseminating high-quality research from its inception in 2004 to its planned convergence in 2024. Its influential position is reflected in its 2023 rankings, placing it in the Q2 category for both Biochemistry and Molecular Biology, alongside respectable Scopus rankings that rank it 118th and 141st in its respective categories. Despite its non-open access structure, Expert Review of Proteomics provides researchers and professionals with a vital platform for critical reviews and insights into proteomic methodologies, thus contributing significantly to the global scientific community. By bridging theoretical research with practical applications, it serves as an essential resource for those dedicated to advancing their knowledge and expertise in this dynamic field.

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

Metabolomics is a distinguished academic journal published by SPRINGER, dedicated to advancing the field of metabolomics and its applications in various biochemistry-related domains. With a focus on innovative research in biochemistry, clinical biochemistry, and endocrinology, diabetes, and metabolism, this journal holds a significant position, being categorized in the Q2 quartile across multiple fields in the 2023 rankings. The journal is indexed with notable metrics: ranking 73rd in Endocrinology, Diabetes and Metabolism and 38th in Clinical Biochemistry on Scopus, demonstrating its impactful contribution to the scientific community. Established in 2005, Metabolomics provides a vital platform for researchers, professionals, and students to access high-quality research, facilitating advancements in our understanding of metabolic processes and their implications in health and disease. Access options include subscription-based reading, ensuring that valuable insights are available to a broad audience across the globe.

Mass Spectrometry Letters is a pioneering open-access journal published by the Korean Society for Mass Spectrometry, specializing in the diverse fields of analytical chemistry, biochemistry, and spectroscopy. Established in 2010, this journal aims to disseminate groundbreaking research and advancements in mass spectrometry and its applications across various scientific domains. Though currently categorized in the Q4 quartile in key analytical fields, Mass Spectrometry Letters serves as an essential platform for researchers, professionals, and students to share innovative methodologies, emerging trends, and practical applications of mass spectrometry, thus fostering collaboration and advancing knowledge in the scientific community. With a commitment to open access, articles published since 2010 are readily available, enabling widespread distribution and engagement within the international research community. Located in Daejeon, South Korea, and actively converging research through 2024, the journal holds the potential to grow its impact and relevance within the dynamic landscape of mass spectrometry.

Proteomes, published by MDPI since 2013, is a notable open access journal that occupies a critical place in the realms of Biochemistry, Clinical Biochemistry, Molecular Biology, and Structural Biology. Based in Switzerland, this journal not only promotes the dissemination of high-quality research pertaining to protein structures and functions but also emphasizes interdisciplinary approaches that bridge various fields of biomedical science. With a Category Quartile ranking of Q2 across multiple pertinent categories in 2023, Proteomes boasts a competitive impact within the scientific community, evidenced by its robust Scopus rankings. Researchers, professionals, and students are invited to explore a wealth of pioneering studies and reviews that are made freely accessible, aligning with global trends in open scientific communication. Whether contributing original research or seeking to expand their knowledge, the journal serves as an invaluable resource for anyone engaged in the evolving landscape of proteomics.

AMYLOID - JOURNAL OF PROTEIN FOLDING DISORDERS, published by Taylor & Francis Ltd, is a premier academic journal dedicated to the crucial field of protein folding disorders, offering a vital platform for researchers and healthcare professionals. With an impressive impact factor and classified in the Q1 quartile across both Internal Medicine and Miscellaneous Medicine categories, this journal ranks within the top 15% of its field according to Scopus, with a remarkable rank of #18 out of 167. Covering interdisciplinary approaches that intersect molecular biology, neuroscience, and clinical implications of amyloidosis and related disorders, AMYLOID encourages the dissemination of innovative research findings from 1994 to 2024 and beyond. Despite lacking Open Access options, the journal remains a significant resource for advancing the understanding of protein misfolding diseases, influencing clinical practice and therapeutic developments. With its longstanding commitment to high-quality research, AMYLOID continues to be an essential reading for scholars, practitioners, and students who aim to make significant contributions to this evolving field.

Molecular Omics is a premier, peer-reviewed journal published by the Royal Society of Chemistry, focusing on the interdisciplinary field of molecular biology with significant implications for biochemistry and genetics. With an E-ISSN of 2515-4184, this journal has been dedicated to disseminating high-quality research since its inception in 2018, maintaining an impressive trajectory in academic contributions until 2024. Currently, it holds a Q2 quartile ranking in both Biochemistry and Genetics, alongside a Q3 ranking in Molecular Biology for 2023, highlighting its relevance and influence in these domains. The journal is accessible as an open access publication, promoting the widespread dissemination of groundbreaking research. As part of a vibrant academic community, Molecular Omics aims to bridge fundamental and applied science, appealing to researchers, professionals, and students eager to expand their knowledge on molecular mechanisms and technologies that shape the future of biological research.

Proteome Science is an esteemed academic journal specializing in the field of proteomics, providing a platform for advanced research and discussions surrounding the structure, function, and dynamics of proteins in biological systems. Published by BMC, a reputable publisher recognized for its commitment to open-access publishing, Proteome Science has been disseminating pivotal research findings since its inception in 2003. Targeted towards researchers, professionals, and students in biochemistry and molecular biology, the journal aims to foster collaboration and innovation within the scientific community. While it currently holds a Q3 quartile ranking in both Biochemistry and Molecular Biology categories, its impactful contributions to the field are reflected in its accessibility, as evidenced by its open access policy. By embracing collaborative research methodologies and providing a platform for novel findings, Proteome Science plays a crucial role in advancing the understanding of proteomic analyses, catering to a global audience that values groundbreaking scientific discovery.

Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.